JP2013544892A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013544892A5 JP2013544892A5 JP2013543331A JP2013543331A JP2013544892A5 JP 2013544892 A5 JP2013544892 A5 JP 2013544892A5 JP 2013543331 A JP2013543331 A JP 2013543331A JP 2013543331 A JP2013543331 A JP 2013543331A JP 2013544892 A5 JP2013544892 A5 JP 2013544892A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- formula
- compound
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 206010066476 Haematological malignancy Diseases 0.000 claims 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000002195 synergetic effect Effects 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42146510P | 2010-12-09 | 2010-12-09 | |
| US61/421,465 | 2010-12-09 | ||
| US201161436258P | 2011-01-26 | 2011-01-26 | |
| US61/436,258 | 2011-01-26 | ||
| US201161467485P | 2011-03-25 | 2011-03-25 | |
| US61/467,485 | 2011-03-25 | ||
| FR1159940 | 2011-11-03 | ||
| FR1159940 | 2011-11-03 | ||
| PCT/US2011/063871 WO2012078832A1 (en) | 2010-12-09 | 2011-12-08 | Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013544892A JP2013544892A (ja) | 2013-12-19 |
| JP2013544892A5 true JP2013544892A5 (enExample) | 2015-01-22 |
Family
ID=45464841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013543331A Abandoned JP2013544892A (ja) | 2010-12-09 | 2011-12-08 | Ｐｉ３ｋ阻害剤及びｍｅｋ阻害剤を含む組成物並びにがんの処置のためのそれらの使用 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20140024653A1 (enExample) |
| EP (1) | EP2648729A1 (enExample) |
| JP (1) | JP2013544892A (enExample) |
| KR (1) | KR20140011311A (enExample) |
| CN (1) | CN103402518A (enExample) |
| AR (1) | AR084216A1 (enExample) |
| AU (1) | AU2011338354A1 (enExample) |
| BR (1) | BR112013014198A2 (enExample) |
| CA (1) | CA2820748A1 (enExample) |
| CL (1) | CL2013001643A1 (enExample) |
| CR (1) | CR20130246A (enExample) |
| DO (1) | DOP2013000131A (enExample) |
| MA (1) | MA34815B1 (enExample) |
| MX (1) | MX2013006319A (enExample) |
| NZ (1) | NZ611581A (enExample) |
| PE (1) | PE20140702A1 (enExample) |
| PH (1) | PH12013501163A1 (enExample) |
| RU (1) | RU2013131241A (enExample) |
| SG (1) | SG190368A1 (enExample) |
| TW (1) | TW201306837A (enExample) |
| UY (1) | UY33790A (enExample) |
| WO (1) | WO2012078832A1 (enExample) |
| ZA (1) | ZA201303687B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2869152A1 (en) * | 2012-04-06 | 2013-10-10 | Sanofi | Methods for treating cancer using pi3k inhibitor and mek inhibitor |
| WO2014056566A1 (en) * | 2012-10-11 | 2014-04-17 | Merck Patent Gmbh | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a mek inhibitor |
| DK3698790T3 (da) | 2014-02-07 | 2023-06-19 | Verastem Inc | Fremgangsmåder til behandling af abnorm cellevækst |
| WO2016014390A1 (en) * | 2014-07-25 | 2016-01-28 | Merck Patent Gmbh | Compositions and methods for mek inhibitor combination therapy in the treatment of cancer |
| KR102747531B1 (ko) * | 2017-12-22 | 2024-12-27 | 아디에네 에스.에이. | 항-cd26 리간드의 생물학적 활성을 결정하기 위한 정량적인 세포적 방법 |
| WO2021047783A1 (en) | 2019-09-13 | 2021-03-18 | The Institute Of Cancer Research: Royal Cancer Hospital | Vs-6063 in combination with ch5126766 for the treatment of cancer |
| CN116568330A (zh) * | 2020-10-16 | 2023-08-08 | 纪念斯隆-凯特琳癌症中心 | 用于癌症治疗的铁死亡诱导 |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
-
2011
- 2011-12-07 AR ARP110104595A patent/AR084216A1/es unknown
- 2011-12-08 AU AU2011338354A patent/AU2011338354A1/en not_active Abandoned
- 2011-12-08 PH PH1/2013/501163A patent/PH12013501163A1/en unknown
- 2011-12-08 NZ NZ611581A patent/NZ611581A/en not_active IP Right Cessation
- 2011-12-08 KR KR1020137017879A patent/KR20140011311A/ko not_active Withdrawn
- 2011-12-08 EP EP11806025.0A patent/EP2648729A1/en not_active Withdrawn
- 2011-12-08 RU RU2013131241/15A patent/RU2013131241A/ru not_active Application Discontinuation
- 2011-12-08 TW TW100145212A patent/TW201306837A/zh unknown
- 2011-12-08 SG SG2013039367A patent/SG190368A1/en unknown
- 2011-12-08 CN CN2011800671706A patent/CN103402518A/zh active Pending
- 2011-12-08 WO PCT/US2011/063871 patent/WO2012078832A1/en not_active Ceased
- 2011-12-08 BR BR112013014198A patent/BR112013014198A2/pt not_active IP Right Cessation
- 2011-12-08 CA CA2820748A patent/CA2820748A1/en not_active Abandoned
- 2011-12-08 JP JP2013543331A patent/JP2013544892A/ja not_active Abandoned
- 2011-12-08 MA MA36091A patent/MA34815B1/fr unknown
- 2011-12-08 MX MX2013006319A patent/MX2013006319A/es not_active Application Discontinuation
- 2011-12-08 PE PE2013001394A patent/PE20140702A1/es not_active Application Discontinuation
- 2011-12-09 UY UY0001033790A patent/UY33790A/es not_active Application Discontinuation
-
2013
- 2013-05-21 ZA ZA2013/03687A patent/ZA201303687B/en unknown
- 2013-05-27 CR CR20130246A patent/CR20130246A/es unknown
- 2013-06-07 CL CL2013001643A patent/CL2013001643A1/es unknown
- 2013-06-07 US US13/912,647 patent/US20140024653A1/en not_active Abandoned
- 2013-06-07 DO DO2013000131A patent/DOP2013000131A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013544892A5 (enExample) | ||
| JP2017518302A5 (enExample) | ||
| JP2013509429A5 (enExample) | ||
| JP2016501221A5 (enExample) | ||
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| JP2015523397A5 (enExample) | ||
| JP2015536964A5 (enExample) | ||
| JP2016536286A5 (enExample) | ||
| JP2013507415A5 (enExample) | ||
| JP2017525730A5 (enExample) | ||
| JP2014509659A5 (enExample) | ||
| WO2011112953A3 (en) | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers | |
| JP2015503596A5 (enExample) | ||
| RU2015106524A (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ ИНГИБИТОРА CDK4/6 И ИНГИБИТОРА В-Raf | |
| RU2015125307A (ru) | Комбинированная терапия | |
| JP2010001302A5 (enExample) | ||
| JP2013542247A5 (enExample) | ||
| JP2014508752A5 (enExample) | ||
| JP2013522326A5 (enExample) | ||
| JP2014530181A5 (enExample) | ||
| GEP201706678B (en) | Method of treating cancer and bone cancer | |
| MX2013011532A (es) | Inhibidores de la proteina 90 de choque termico (hsp90). | |
| JP2015511609A5 (enExample) | ||
| JP2015193630A5 (enExample) | ||
| JP2015502926A5 (enExample) |